Trials / Unknown
UnknownNCT05674565
Magnesium Sulphate Neuroprotective Strategies for Preterm Deliveries
The Neuroprotective Impact of Magnesium Sulphate Therapy for Preterm Deliveries. Loading Dose Alone Strategy Versus Loading Plus Maintenance Dose Strategy.
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 336 (estimated)
- Sponsor
- Zagazig University · Other Government
- Sex
- All
- Age
- 24 Weeks – 34 Weeks
- Healthy volunteers
- Not accepted
Summary
A Cochrane systematic review has confirmed that fetal exposure to magnesium sulphate given before preterm birth has a neuroprotective role. This review also showed a significant reduction in the rate of gross motor dysfunction in early childhood. Early Preterm birth (\< 34+0 weeks) and very low birthweight (\< 1,500 g) are the principal risk factors for cerebral palsy. Multiple pregnancy accounts for over 10% of preterm births and has a higher incidence of cerebral palsy than singleton pregnancy (twins have 7 times and triplets 47 times the risk of cerebral palsy compared with singletons).
Detailed description
Many of these patients come or get diagnosed as eminent preterm delivery very soon before the real delivery happens and are not able to complete the recommended therapy of loading and maintenance strategy for at least complete 4 hours before delivery. Till now, there is a gap and lack of knowledge regarding the value of loading dose only as sufficient and effective strategy for neuroprotection compared to full therapy, which needs more health costs, longer monitoring and carries more risk for the patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Magnesium sulfate loading with maintenance dose | 4 gm MgSo4 loading over 20 minutes followed by 1 gm per hour maintenance till delivery |
| DRUG | Magnesium sulfate loading dose only | 4 gm MgSo4 loading over 20 minutes within one hour before delivery |
Timeline
- Start date
- 2023-01-20
- Primary completion
- 2024-06-30
- Completion
- 2024-07-15
- First posted
- 2023-01-06
- Last updated
- 2023-07-14
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT05674565. Inclusion in this directory is not an endorsement.